scholarly journals Use of clozapine in Brazilian patients with Parkinson's disease

2008 ◽  
Vol 66 (3b) ◽  
pp. 611-614 ◽  
Author(s):  
Laura Gomide ◽  
Arthur Kummer ◽  
Francisco Cardoso ◽  
Antonio Lucio Teixeira
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adverse Effects ◽  
Chart Review ◽  
Maximum Dose ◽  
Retrospective Chart Review ◽  
Advanced Parkinson’S Disease ◽  
Brazilian Sample ◽  
Average Maximum ◽  
Psychiatric Complications

Clozapine has been used as an attempt to manage levodopa complications in advanced Parkinson's disease (PD). To investigate the use of clozapine in this context in a Brazilian sample, a retrospective chart review was carried out at the Movement Disorders Clinic from the Federal University of Minas Gerais. This study enrolled 43 PD patients who used or were in use of clozapine. Patients had a mean age of 64 years and a mean UPDRS score of 55. Clozapine was indicated for dyskinesias in 17 patients, for psychosis in 15 and for both reasons in 11. The average maximum dose was 70 mg/day. Twenty six patients used it for a mean of 3.5 years. Twenty nine presented an improvement of their condition, 9 remained clinically stable. Twenty subjects interrupted the use of clozapine, being 9 due to adverse effects. Clozapine may play a role in the management of motor and psychiatric complications in PD, but it is associated with low tolerability.

scholarly journals P.123 Normal pressure hydrocephalus with associated tremor

2019 ◽  
Vol 46 (s1) ◽  
pp. S45-S46
Author(s):  
A Persad ◽  
K Meguro
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Normal Pressure Hydrocephalus ◽  
Chart Review ◽  
Functional Decline ◽  
Retrospective Chart Review ◽  
Normal Pressure ◽  
Careful Consideration ◽  
The Other ◽  
Extrapyramidal Signs

Background: Normal pressure hydrocephalus is a frequent cause of cognitive and functional impairment. Many symptoms are shared between Parkinson’s disease and normal pressure hydrocephalus. Only few studies examine extrapyramidal signs in NPH, and only one case report exists describing tremor improvement with shunting. Methods: We performed a retrospective chart review of our NPH database. We selected patients who had both NPH and question of Parkinsonism due to tremor. Results: Six patients with both NPH diagnosis and tremor were identified. Three patients were treated for Parkinson’s disease and followed by neurology. After shunting, all three improved and attempt was made to wean medications, which led to functional decline. The other three patients improved with shunting and after titration of the shunt had resolution of tremor. Conclusions: We provide evidence that NPH can result in tremor, treatable by shunting. We also emphasize that those patients do exist who have both diseases. This likely exists along a continuum. Careful consideration of NPH should be undertaken in those patients with suspected Parkinson’s disease and imaging findings reminiscent of NPH.

scholarly journals Natural History and Patterns of Treatment Change in Parkinson’s Disease: A Retrospective Chart Review

2021 ◽  
pp. 100125
Author(s):  
Prakash Navaratnam ◽  
Steve Arcona ◽  
Howard S. Friedman ◽  
Matthew Leoni ◽  
Shajahan Shaik ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Natural History ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Treatment Change

scholarly journals Bromocriptine in the Management of End of Dose Deterioration in Parkinson’s Disease

1984 ◽  
Vol 11 (4) ◽  
pp. 452-456 ◽  
Author(s):  
J.D. Grimes ◽  
D.B. King ◽  
O.S. Kofman ◽  
P. Molina-Negro ◽  
A.F. Wilson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adverse Effects ◽  
Early Treatment ◽  
Disability Score ◽  
Advanced Parkinson’S Disease ◽  
Daily Dose ◽  
Small Doses ◽  
The Mean

ABSTRACTThirty-three patients with advanced Parkinson’s disease complicated by end of dose deterioration were treated with bromocriptine. The drug was slowly increased so that by treatment week 24 the mean daily dose of bromocriptine was 22mg and levodopa had been decreased by an average of 15 percent. The majority of improvement in daily fluctuations and Parkinsonian disability score was documented by 8 weeks, at which time the mean daily bromocriptine dose was only 12mg.End of dose deterioration was reduced in 78 percent of the patients (mean 43% improvement). Total Parkinsonian disability score was decreased by 33 percent. Adverse effects were minimal; the most common was mild transient early treatment nausea which occurred in 15 percent of the patients.The slow introduction of small doses of bromocriptine, combined with minimal levodopa reduction, can give Parkinsonian patients significant improvement in end of dose deterioration.

scholarly journals Method of Addition of Bromocriptine to the Drug Regime of Patients with Advanced Parkinson’s Disease

1981 ◽  
Vol 8 (1) ◽  
pp. 31-34 ◽  
Author(s):  
J. David Grimes ◽  
Mohamed N. Hassan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adverse Effects ◽  
Gradual Increase ◽  
Advanced Parkinson’S Disease ◽  
Number Of Patients ◽  
Concomitant Reduction

SUMMARYUsing a method of a gradual increase of bromocriptine with a concomitant reduction of Sinemet® (levodopa 250 mg + carhidopa 25 mg), 19 patients with advanced Parkinson’s disease have been treated for periods of up to 22 months and 16 of them have shown improvements of varying degrees. Eighteen patients were able to tolerate bromocriptine addition, with early transient adverse effects occurring in seven cases. In contrast to several previously reported studies, it was found necessary to withdraw bromocriptine in only one case.With the drugs currently available, bromocriptine has a role in the management of patients with advanced Parkinson’s disease. The method described here may allow a greater number of patients to be given a trial with this drug.

scholarly journals Prevalence of essential tremor in an idiopathic Parkinson’s disease patient population

2015 ◽  
Vol 42 (S1) ◽  
pp. S31-S31
Author(s):  
A Rana ◽  
AM Qureshi ◽  
MA Rana ◽  
M Rahman ◽  
I Abdullah ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
General Population ◽  
Essential Tremor ◽  
Chart Review ◽  
Disease Patient ◽  
Retrospective Chart Review ◽  
Type Frequency ◽  
Exact Relationship ◽  
Mutually Independent

Objective of this study was assess the prevalence of Essential of Essential Tremor in Parkinson’s disease population Essential tremor (ET) is the most common movement disorders and is much more common than Parkinson’s disease, in general population. Essential Tremor and Parkinson’s disease (PD) tremor differ in type, frequency and distribution. Despite being two separate disorders, there have been cases reported of coexistence of ET-PD. Some studies have reported an increase in the incidence of ET in relatives of patients with PD, yet the risk of developing PD in ET patients has not been thoroughly investigated. Our study set out to determine the prevalence of precedent ET in PD patients. We conducted a retrospective chart review analysis of 332 idiopathic PD patients to determine how many of them had ET prior to the diagnosis of PD and the percentage of them who were also diagnosed with ET. Our results indicated that the prevalence of precedent ET among a population of idiopathic PD patients was not any higher than the prevalence of ET in a comparable general population. Our results support the notion that ET and PD are mutually independent disorders. Further studies are needed to understand the exact relationship between these two disorders

scholarly journals Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review

Drugs & Aging ◽  
2019 ◽  
Vol 36 (7) ◽  
pp. 647-653 ◽  
Author(s):  
Jessie Sellers ◽  
R. Ryan Darby ◽  
Alma Farooque ◽  
Daniel O. Claassen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Chart Review ◽  
Retrospective Chart Review

scholarly journals Deprenyl in Parkinson’s Disease: Mechanisms, Neuroprotective Effect, Indications and Adverse Effects

1992 ◽  
Vol 19 (S1) ◽  
pp. 142-146 ◽  
Author(s):  
Paul Vezina ◽  
Erich Mohr ◽  
David Grimes
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adverse Effects ◽  
Neuroprotective Effect ◽  
Dopamine Neurons ◽  
Advanced Parkinson’S Disease ◽  
Ulcer Disease ◽  
Daily Dose ◽  
Higher Doses ◽  
Symptomatic Benefit

ABSTRACT:Deprenyl is a synthetic, selective inhibitor of the monoamine oxidase-B enzyme system. The mechanism of its beneficial effect in early and advanced Parkinson’s disease is not settled. Increased striatal dopamine accumulation, sensitization of surviving dopamine neurons with increased dopamine production and reduced nigro-striatal toxicity may all contribute. The standard daily dose of deprenyl is 10 mg. Selectivity may be lost at higher doses. Deprenyl is especially indicated in untreated patients, improving up to 50 percent of patients with mild motor fluctuations. Major symptomatic benefit also occurs in occasional levodopa treated patients. Adverse effects are common, however. Increase dyskinesias, confusion and hallucinations, nausea and postural hypotension may necessitate drug withdrawal or the use of low dose regimens. Caution should be exercised with older patients, those with ulcer disease, which may be worsened by deprenyl, and individuals with active ischemic heart disease where the safety of this drug is not yet clear.

Sign in / Sign up

Export Citation Format

Share Document